GlassScriptPhysician profile
Vernon E Taylor
NPI 1326380304
$5,167.26
in general payments reported to CMS, 2019-2025
27 companies · $812 in 2025
The $812 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,230 · 2022: $830 · 2023: $1,093 · 2024: $1,201 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,013 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,012.77 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $905.85 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $641.28 | 2021-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $574.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $537.18 | 2021-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $507.82 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $480.52 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $217.08 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $207.79 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $165.41 | 2021-2024 | Rexulti, Abilify Maintena |
| Astellas Pharma US INC | $152.52 | 2021-2023 | |
| Amarin Pharma, INC. | $112.87 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $94.40 | 2021 | |
| Pfizer INC. | $79.22 | 2021-2025 | |
| Glaxosmithkline, LLC. | $68.62 | 2022-2023 | Trelegy Ellipta |
| Vanda Pharmaceuticals INC. | $65.01 | 2024-2025 | Fanapt, Hetlioz |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $56.47 | 2021 | |
| Abbott Laboratories | $50.92 | 2022-2023 | Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.85 | 2022-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $44.64 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $34.15 | 2021-2022 | |
| Indivior INC. | $32.73 | 2024-2025 | Sublocade |
| Xeris Pharmaceuticals, INC. | $20.90 | 2025 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $15.08 | 2022 | |
| Mylan Specialty L.P. | $14.08 | 2021 | |
| Dexcom, INC. | $13.07 | 2024 | Dexcom G6 Transmitter |
| Jazz Pharmaceuticals INC. | $12.96 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vernon Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.